Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7190-7194

  Sapra, Puja ^a   Allenz, Theresa M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CHOLESTEROL; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; EPITOPE; IMMUNOLIPOSOME; MACROGOL 2000; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD19; MONOCLONAL ANTIBODY CD20; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CONFOCAL MICROSCOPY; CONJUGATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD19; ANTIGENS, CD20; DOXORUBICIN; EPITOPES; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTOXINS; LIPOSOMES; LYMPHOMA, B-CELL; MICE; MICE, SCID; MICROSCOPY, CONFOCAL; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037115543     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Maruyama, K., Takahashi, N., Tagawa, T., Nagaike, K., and Iwatsuru, M. Immunoliposomes bearing polyethyleneglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett., 413: 177-180, 1997.
2. Lopes de Menezes, D. E., Pilarski, L. M., and Allen, T. M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res., 58: 3320-3330, 1998.
3. Sugano, M., Egilmez, N. K., Yokota, S. J., Chen, F. A., Harding, J., Huang, S. K., and Bankert, R. B. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res., 60: 6942-6949, 2000.
4. Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U. B., Marks, J. D., Moore, D., Papahadjopoulos, D., and Benz, C. C. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002.
5. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2: 750-763, 2002.
6. Goren, D., Horowitz, A. T., Zalipsky, S., Woodle, M. C., Yarden, Y., and Gabizon, A. Targeting of stealth liposomes to erB-2 (Her/2) receptor: In vitro and in vivo studies. Br. J. Cancer, 74: 1749-1756, 1996.
7. Vingerhoeds, M. H., Steerenberg, P. A., Hendriks, J. J. G. W., Kekker, L. C., van Hoesel, Q. G. C. M., Crommelin, D. J. A., and Storm, G. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br. J. Cancer, 74: 1023-1029, 1996.
8. Allen, T. M., Hansen, C. B., Martin, F., Redemann, C., and Yau-Young, A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta, 1066: 29-36, 1991.
9. Zola, H., Macardle, P. J., Bradford, T., Weedon, H., Yasui, H., and Kurosawa, Y, Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol. Cell Biol., 69: 411-422, 1991.
10. Iden, D. L., and Allen, T. M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion technique. Biochim. Biophys. Acta, 1513: 207-216, 2001.
11. Lopes de Menezes, D. E., Kirchmeier, M. J., Gagne, J-F., Pilarski, L. M., and Allen, T. M. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. J. Liposome Res., 9: 199-228, 1999.
12. Bolotin, E. M., Cohen, R., Bar, L. K., Emanuel, S. N., Lasic, D. D., and Barenholz, Y. Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandosomes. J. Liposome Res., 4: 455-479, 1994.
13. Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W-L., Carter, P., Benz, C. C., and Papahadjopoulos, D. Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro. Biochemistry, 36: 66-75, 1997.
14. Uckun, F. M., Jaszcz, W., Ambrus, J. L., Fauci, A. S., Gajl-Peczalska, K., Song, S. W., Wick, M. R., Myers, D. E., Waddick, K., and Ledbetter, J. A. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood, 71: 13-29, 1988.
15. Press, O. W., Farr, A. G., Borroz, K. I., Andersen, S. K., and Martin, P. J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res., 49: 4906-4912, 1989.
16. van Oosterhout, Y. V. J. M., van den Herik-Oudijk, I. E., Wessels, H. M. C., de Witte, T., van de Winkel, J. G. J., and Preijers, F. W. M. B. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Res., 54: 3527-3532, 1994.
17. Press, O. W., Appelbaum, F., Ledbetter, J. A., Martin, P. J., Zarling, J., Kidd, P., and Thomas, E. D. Monoclonal antibody IF5 (anti-CD20) serotherapy of human B cell lymphomas. Blood, 69: 584-591, 1987.
18. Kirchmeier, M. J., Ishida, T., Chevrette, J., and Allen, T. M. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J. Liposome Res., 11: 15-29, 2001.
19. Ishida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S., and Allen, T. M. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta, 1515: 144-158, 2001.
20. Poul, M. A., Becerril, B., Nielsen, U. B., Morisson, P., and Marks, J. D. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol., 301: 1149-1161, 2000.